| Literature DB >> 34089909 |
Mohammad Mahfuz Ali Khan Shawan1, Ashish Ranjan Sharma2, Manojit Bhattacharya3, Bidyut Mallik4, Farhana Akhter5, Md Salman Shakil6, Md Mozammel Hossain7, Subrata Banik7, Sang-Soo Lee8, Md Ashraful Hasan9, Chiranjib Chakraborty10.
Abstract
The devastating outbreak of COVID-19 has spread all over the world and has become a global health concern. There is no specific therapeutics to encounter the COVID-19. Small interfering RNA (siRNA)-based therapy is an efficient strategy to control human viral infections employing post-transcriptional gene silencing (PTGS) through neutralizing target complementary mRNA. RNA-dependent RNA polymerase (RdRp) encoded by the viral RdRp gene as a part of the replication-transcription complex can be adopted as an acceptable target for controlling SARS-CoV-2 mediated infection. Therefore, in the current study, accessible siRNA designing tools, including significant algorithms and parameters, were rationally used to design the candidate siRNAs against SARS-COV-2 encoded RdRp. The designed siRNA molecules possessed adequate nucleotide-based and other features for potent gene silencing. The targets of the designed siRNAs revealed no significant matches within the whole human genome, ruling out any possibilities for off-target silencing by the siRNAs. Characterization with different potential parameters of efficacy allowed selecting the finest siRNA among all the designed siRNA molecules. Further, validation assessment and target site accessibility prediction also rationalized the suitability of this siRNA molecule. Molecular docking study between the selected siRNA molecule and component of RNA interference (RNAi) pathway gave an excellent outcome. Molecular dynamics of two complexes: siRNA and argonaute complex, guide RNA, and target protein complex, have shown structural stability of these proteins. Therefore, the designed siRNA molecule might act as an effective therapeutic agent against the SARS-CoV-2 at the genome level and can prevent further outbreaks of COVID-19 in humans.Entities:
Keywords: COVID-19; Post-transcriptional gene silencing; RNA-dependent RNA polymerase; SARS-CoV-2; siRNA
Year: 2021 PMID: 34089909 PMCID: PMC8170914 DOI: 10.1016/j.meegid.2021.104951
Source DB: PubMed Journal: Infect Genet Evol ISSN: 1567-1348 Impact factor: 3.342
Fig. 1The complete methodology to design and predict effective siRNA molecules against RdRp gene sequences of SARS-CoV-2.
Algorithms/rules for rational designing of siRNA molecules.
| Ui-Tei rules | Amarzguioui rules | Reynolds rules |
|---|---|---|
The 5′ terminus of the sense/passenger strand must include G/C The 5′ terminus of the antisense/guide strand need to contain A/U The 5′ terminal 7 base pair of sense/passenger strand should have at least 4 A/U The length of GC stretch no longer than 9 nucleotides | The A/U differential of the duplex end should be >0 Robust attachment of 5′ sense/passenger strand Position 1 must have any bases other than U Position 6 must have A constantly Weak attachment of 3′ sense/passenger strand. Position 19 must contain any bases other than G | The designed siRNA must maintain a GC content between 30% to 52% (1 point) The sense/passenger strand need to maintain ≥3 A/U base pairs at the position between 15 and 19 (Within this domain every A/U = 1 point) The Tm (melting temperature) of designed siRNA must be greater than −20 °C (1 point) Position 19 of sense/passenger strand must contain A (1 point) Position 3 of sense/passenger strand must include A (1 point) Position 10 of the sense/passenger strand should have U (1 point) Position 13 of the sense/passenger strand must contain any bases other than G (1 point) The threshold value (score) for an effective siRNA should be ≥ 6 |
Consensus target revealed through multiple sequence alignment of the targets obtained by siDirect 2.0.
| Consensus target sequence no. | Consensus target sequences |
|---|---|
| 1 | GTGTCTCTATCTGTAGTACTATG |
| 2 | GACTTTATGAGTGTCTCTATAGA |
| 3 | TAGTACTATGAC-CAATAGACAGT |
| 4 | GACCAATAGACAGTTTCATCAAA |
| 5 | ATGAAGTATTTTGTGAAAATAGG |
| 6 | TTGGAATGTAGTGCGTATAAAGA |
| 7 | GCGTATAAAGATTGTACAAATGT |
| 8 | TGCTAATAGTGTTTTTAACATTT |
| 9 | ATCTACTGATGGTAACAAAATTG |
| 10 | ATCAAAAATTATTGAAATCAATA |
| 11 | ATGCCATTAGTGCAAAGAATAGA |
| 12 | CCCTACTATAACTCAAATGAATC |
| 13 | GGCTAGCATAAAGAACTTTAAGT |
| 14 | ATGTTAAGTGACACACTTAAAAA |
| 15 | TGGCTTTGAGTTGACATCTATGA |
| 16 | TTGGATTTGATTACGTCTATAAT |
| 17 | TGGCATCATTCTATTGGATTTGA |
| 18 | TGCCTAACATGCTTAGAATTATG |
| 19 | GCCTAACATGCTTAGAATTATGG |
| 20 | TGCGTAAACATTTCTCAATGATG |
| 21 | ATGCACTTTTCGCATATACAAAA |
| 22 | GCCAATGTTAATGCACTTTTATC |
Consensus target sequences of SARS-CoV-2 RdRp gene revealed through multiple sequence alignment of the targets obtained by RNAxs web server.
| Consensus target sequence no. | Consensus target sequences |
|---|---|
| A | GGCCAATGTTAATGCACTT |
| B | GCCAATGTTAATGCACTTT |
| C | GCTAGCATAAAGAACTTTA |
| D | TCCACTGCTTCAGACACTT |
| E | CCCTACTATAACTCAAATG |
| F | TCCCTACTATAACTCAAAT |
| G | GACATCTATGAAGTATTTT |
| H | TGACATCTATGAAGTATTT |
| I | CACACCGTTTCTATAGATT |
| J | GCTTGTCACACCGTTTCTA |
| K | CGGTTCACTATATGTTAAA |
| L | CGGTTCACTATATGTTAAA |
| M | TCAGTTCTTTATTATCAAA |
| N | TCTCTATCTGTAGTACTAT |
| O | AGACAGTTTCATCAAAAAT |
| P | GACAGTTTCATCAAAAATT |
| Q | ACAGTTTCATCAAAAATTA |
| R | CAGTTTCATCAAAAATTAT |
| S | TCTTTATTATCAAAACAAT |
| T | AGTAATTGGAACAAGCAAA |
| U | CCTAACATGCTTAGAATTA |
| V | AGGACTTCCTTGGAATGTA |
| W | CGCATATACAAAACGTAAT |
| X | GCATATACAAAACGTAATG |
| Y | GGATTATCCTAAATGTGAT |
Multiple sequence alignment of targets obtained by siDirect 2.0 and RNAxs server.
| Consensus target sequences no. | Consensus target sequences obtained by siDirect 2.0 and RNAxs server |
|---|---|
| 12 | ----------CCCTACTATAACTCAAATGAATC-- |
| E | ----------CCCTACTATAACTCAAATG---------- |
| F | -----------TCCCTACTATAACTCAAAT--------- |
| 19 | ----------GCCTAACATGCTTAGAATTATGG-- |
| U | -------------CCTAACATGCTTAGAATTA-------- |
| 18 | --------TGCCTAACATGCTTAGAATTATG---- |
| 3 | ------TAGTACTATGACCAATAGACAGT------ |
| T | ---------AGTAATTGGAACAAGCAAA----------- |
| 13 | -----ATGTTAAGTGACACACTTAAAAA------- |
| O | ------------AGACAGTTTCATCAAAAAT--------- |
| P | -------------GACAGTTTCATCAAAAATT-------- |
| Q | --------------ACAGTTTCATCAAAAATTA------- |
| R | ---------------CAGTTTCATCAAAAATTAT------ |
| 4 | --GACCAATAGACAGTTTCATCAAA---------- |
| 8 | --------TGCTAATAGTGTTTTTAACATTT------ |
| D | --------------TCCACTGCTTCAGACACTT------- |
| 13 | ----------GGCTAGCATAAAGAACTTTAAGT-- |
| C | ------------GCTAGCATAAAGAACTTTA-------- |
| 22 | -----------GCCAATGTTAATGCACTTTTATC-- |
| B | -----------GCCAATGTTAATGCACTTT---------- |
| A | ------------GGCCAATGTTAATGCACTT--------- |
| 9 | --------- ATCTACTGATGGTAACAAAATTG --- |
| G | -------------GACATCTATGAAGTATTTT-------- |
| H | ------------TGACATCTATGAAGTATTT--------- |
| 5 | --------ATGAAGTATTTTGTGAAAATAGG---- |
| 10 | --------ATCAAAAATTATTGAAATCAATA ---- |
| V | -----------AGGACTTCCTTGGAATGTA---------- |
| 17 | ---------TGGCATCATTCTATTGGATTTGA----- |
| Y | -------------GGATTATCCTAAATGTGAT--------- |
| W | ------------CGCATATACAAAACGTAAT--------- |
| X | --------------GCATATACAAAACGTAATG------- |
| 21 | ATGCACTTTTCGCATATACAAAA------------- |
| 7 | -----------GCGTATAAAGATTGTACAAATGT- |
| 20 | -----------TGCGTAAACATTTCTCAATGATG-- |
| 1 | -------------GTGTCTCTATCTGTAGTACTATG |
| N | -------------------TCTCTATCTGTAGTACTAT--- |
| K | -------------CGGTTCACTATATGTTAAA--------- |
| I | --------------------CACACCGTTTCTATAGATT-- |
| J | -------------GCTTGTCACACCGTTTCTA--------- |
| 2 | -----------GACTTTATGAGTGTCTCTATAGA--- |
| 15 | ---------- TGGCTTTGAGTTGACATCTATGA --- |
| 16 | ---------- TTGGATTTGATTACGTCTATAAT--- |
| 6 | ----------TTGGAATGTAGTGCGTATAAAGA-- |
| 14 | ----------- ATGTTAAGTGACACACTTAAAAA ---- |
| L | --------------- CGGTTCACTATATGTTAAA -------- |
| M | ---------------TCAGTTCTTTATTATCAAA--------- |
| S | --------------------TCTTTATTATCAAAACAAT--- |
Proposed siRNA molecules and their consensus target of RdRp gene sequence from SARS-CoV-2 with GC%, free energy of folding, free energy of binding with target and heat capacity.
| Target | siRNA consensus target sequence 21 nt target + 2 nt overhang (5′ → 3′) | Predicted siRNA duplex at 37 °C 21 nt guide (5′ → 3′) | GC% | ΔG of folding (kcal/mol) | ΔG of binding (kcal/mol) | TmCp (°C) | TmConc. (°C) |
|---|---|---|---|---|---|---|---|
| Consensus Target-1 | GTGTCTCTATCTGTAGTACTATG | UAGUACUACAGAUAGAGACAC | 38.09 | 0.1 | −35.2 | 79.3 | 80.6 |
| GUCUCUAUCUGUAGUACUAUG | |||||||
| Consensus Target-12 | CCCTACTATAACTCAAATGAATC | UUCAUUUGAGUUAUAGUAGGG | 30.95 | – | −32.0 | 72.6 | 73.8 |
| CUACUAUAACUCAAAUGAAUC | |||||||
| Consensus Target-13 | GGCTAGCATAAAGAACTTTAAGT | UUAAAGUUCUUUAUGCUAGCC | 30.95 | – | −31.8 | 73.7 | 75.1 |
| CUAGCAUAAAGAACUUUAAGU | |||||||
| Consensus Target-18 | TGCCTAACATGCTTAGAATTATG | UAAUUCUAAGCAUGUUAGGCA | 33.33 | −1.4 | −32.5 | 76.2 | 77.4 |
| CCUAACAUGCUUAGAAUUAUG | |||||||
| Consensus Target-19 | GCCTAACATGCTTAGAATTATGG | AUAAUUCUAAGCAUGUUAGGC | 33.33 | −1.4 | −32.1 | 74.1 | 75.3 |
| CUAACAUGCUUAGAAUUAUGG | |||||||
| Consensus Target-22 | GCCAATGTTAATGCACTTTTATC | UAAAAGUGCAUUAACAUUGGC | 33.33 | −0.4 | −31.6 | 79.2 | 80.5 |
| CAAUGUUAAUGCACUUUUAUC |
Fig. 2The possible folding and minimum free energy of the guide strands of the predicted siRNA molecules computed using with the online RNA structure web server. A) consensus target 1 siRNA; B) consensus target 18 siRNA; C) consensus target 19 siRNA; D) consensus target 22 siRNA. Secondary structure of siRNA 11 and siRNA 12 could not be predicted.
Fig. 3Predicted lowest free energy structure for binding of target RNA with the guide strand of A) consensus target 1 siRNA, B) consensus target 11 siRNA, C) consensus target 12 siRNA, D) consensus target 18 siRNA, E) consensus target 19 siRNA and F) consensus target 22 siRNA.
Fig. 4Considerable profiles of consensus target 1 siRNA target site accessibility prediction. A) Probability profile, B) Hairpin loop (Hplot) profile, C) Bulge loop (Bplot) profile, D) Interior loop (Iplot) profile, E) Multi branched loop (Mplot) profile of target mRNA, and F) Internal stability profile of consensus target 1 siRNA for target position 15–33.
Fig. 53D interaction diagram of different docked complex. A) guide (red)-passenger (blue), B) siRNA‑argonaute, C) siRNA‑argonaute (extended view) and D) guide (red)-target (blue).
Fig. 6Molecular Dynamics (MD) simulation of guide siRNA‑argonaute complex A) Root Mean Square deviations (RMSD) plot, B) Root mean square Fluctuation (RMSF) plot.
Fig. 7Molecular Dynamics (MD) simulation of target protein-siRNA docked complex A) Root Mean Square Fluctuation (RMSF) plot, B) Root mean square deviations (RMSD) plot.
Fig. 8Proposed mechanism of action of the designed siRNA showing the PTGS of RdRp gene from SARS-CoV-2.